Rebecca Brauner
Nurse Practitioner · Louisville, KYNPI 1871526970
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,750 of the $40,354 with a category attached, or 61.3%. AstraZeneca accounts for 84.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $16,221 and has fallen 51.8% since, to $7,826 in 2025. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $201.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- Actelion Pharmaceuticals US, Inc.$2K
- Verona Pharma, Inc.$853
- GSK$693
- Boehringer Ingelheim$689
- Merck$352
- plus $2K from 15 others
What the payments were for
- Consulting fees$4,72512%
- Speaking & faculty fees$24,75061%
- Travel & lodging$2,6387%
- Food & beverage$8,24220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $34,016 |
| Actelion Pharmaceuticals US, Inc. | 17 | $1,613 |
| Verona Pharma, Inc. | 6 | $853 |
| GSK | 28 | $693 |
| Boehringer Ingelheim | 50 | $689 |
| Merck | 4 | $352 |
| Inari Medical, Inc. | 2 | $283 |
| Grifols USA, LLC | 6 | $269 |
| Sanofi | 2 | $242 |
| Mylan Specialty L.p. | 2 | $155 |
| Insmed, Inc. | 1 | $137 |
| Bayer | 2 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $127 |
| Jazz Pharmaceuticals Inc. | 1 | $118 |
| Regeneron Healthcare Solutions, Inc. | 1 | $112 |
| United Therapeutics Corporation | 1 | $111 |
| Pfizer | 1 | $111 |
| AbbVie | 1 | $105 |
| Mallinckrodt Hospital Products Inc. | 1 | $88 |
| Philips North America LLC | 1 | $73 |
| Grifols Shared Services North America, Inc. | 1 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$32,418
- OPSUMIT$1,177
- UPTRAVI$1,162
- Ohtuvayre$837
- DUPIXENT$354
- FASENRA$353
- TEZSPIRE$250
- Prolastin-C Liquid$245
- FLOWTRIEVER CATHETER, S$235
- CT THROMBECTOMY SYSTEM KIT$235
- OFEV$226
- NUCALA$212
- Arikayce$137
- GLASSIA$121
- TRELEGY ELLIPTA$120
- AIRSUPRA$120
- XYWAV$118
- AREXVY$113
- REMODULIN$111
- TYVASO$111
How this compares
$40,354 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 394 | $312,497 |
| OpsumitMacitentan | 15 | $184,847 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 128 | $105,825 |
| Spiriva RespimatTiotropium Bromide | 149 | $105,054 |
| Breo ElliptaFluticasone/Vilanterol | 143 | $63,199 |
| Dupixent PenDupilumab | 11 | $41,114 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $19,803 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $19,763 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $15,628 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $14,930 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $12,859 |
| Spiriva HandihalerTiotropium Bromide | 11 | $9,084 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 278 | $9,027 |
| Ventolin HfaAlbuterol Sulfate | 74 | $5,155 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $693 | $410,264622 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,613 | $184,84715 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $34,016 | $125,587176 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $689 | $124,857183 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Louisville
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Thomas FreelsLouisville$20K
- Christy BakerLouisville$18K
- Blair WagnerLouisville$15K
- Kathryn WestLouisville$13K
- Kimberly RobinsonLouisville$13K
- Mistie TeerLouisville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.